Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Adrienne H. Long"'
Autor:
Agnes Reschke, Rebecca M. Richards, Stephanie M. Smith, Adrienne H. Long, Lianna J. Marks, Liora Schultz, Jennifer L. Kamens, Catherine Aftandilian, Kara L. Davis, Tanja Gruber, Kathleen M. Sakamoto
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
Clinical pathways are evidence-based tools that have been integrated into many aspects of pediatric hospital medicine and have proven effective at reducing in-hospital complications from a variety of diseases. Adaptation of similar tools for specific
Externí odkaz:
https://doaj.org/article/8332e18e0fec4a0eaad8f1efab2764b2
Publikováno v:
American Society of Clinical Oncology Educational Book. :781-794
The role of immune checkpoint inhibitors (ICIs) in the treatment of pediatric cancers continues to evolve. Such therapies function by augmenting existing antitumor T-cell responses that have been rendered ineffective by inhibitory pathways. Although
Autor:
Crystal L. Mackall, Rimas J. Orentas, Maria G. Tsokos, Susana Galli, Rana El-Etriby, Sneha Ramakrishna, Alec J. Walker, Jillian P. Smith, Yongzhi Cui, Steven L. Highfill, Adrienne H. Long
Increased number of MDSCs present in sarcoma tumor-bearing mice, but not in neuroblastoma tumor-bearing mice.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::620353379dfb29c5a02b5f51f2a1501e
https://doi.org/10.1158/2326-6066.22537844
https://doi.org/10.1158/2326-6066.22537844
Data from Reduction of MDSCs with All-trans Retinoic Acid Improves CAR Therapy Efficacy for Sarcomas
Autor:
Crystal L. Mackall, Rimas J. Orentas, Maria G. Tsokos, Susana Galli, Rana El-Etriby, Sneha Ramakrishna, Alec J. Walker, Jillian P. Smith, Yongzhi Cui, Steven L. Highfill, Adrienne H. Long
Genetically engineered T cells expressing CD19-specific chimeric antigen receptors (CAR) have shown impressive activity against B-cell malignancies, and preliminary results suggest that T cells expressing a first-generation disialoganglioside (GD2)-s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ac2399c9415c13ea5c778d3bf055d0e2
https://doi.org/10.1158/2326-6066.c.6548570.v1
https://doi.org/10.1158/2326-6066.c.6548570.v1
Autor:
Crystal L. Mackall, Rimas J. Orentas, Maria G. Tsokos, Susana Galli, Rana El-Etriby, Sneha Ramakrishna, Alec J. Walker, Jillian P. Smith, Yongzhi Cui, Steven L. Highfill, Adrienne H. Long
GD2 expression on pediatric sarcomas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::595e7c59da3639342f8a9c0ae0a55a39
https://doi.org/10.1158/2326-6066.22537832
https://doi.org/10.1158/2326-6066.22537832
Autor:
John G. Doench, Flavian D. Brown, Dawn E. Comstock, Kathleen B. Yates, Juan Dubrot, Robert T. Manguso, Hans W. Pope, W. Nicholas Haining, Austin Ayer, Adrienne H. Long, Arpit Panda, Ian C. Kohnle, Peter P. Du, Margaret D. Zimmer, Erez Y. Levanon, Jeffrey J. Ishizuka, Gabriel K. Griffin, Sarah Kate Lane-Reticker, Kevin Bi, David Kozono, Ilana Buchumenski, Natalie B. Collins, Collins K. Cheruiyot, Brian C. Miller, Emily J. Robitschek, Debattama R. Sen, Arvin Iracheta-Vellve
Publikováno v:
Signal Transduction and Targeted Therapy
Most patients with cancer either do not respond to immune checkpoint blockade or develop resistance to it, often because of acquired mutations that impair antigen presentation. Here we show that loss of function of the RNA-editing enzyme ADAR1 in tum
Autor:
Caroline Diorio, Raul Montiel-Esparza, Susan R. Rheingold, L. Charles Bailey, Adrienne H. Long, Yang-Yang Ding, Stephen P. Hunger, Richard Aplenc, Shannon L. Maude, Sneha Ramakrishna, Anne Reilly, Norman J. Lacayo, Charles A. Phillips, Kathleen M. Sakamoto, Vandana Batra
Publikováno v:
Pediatric Blood & Cancer
Autor:
Adrienne H. Long, Rimas J. Orentas, Steven L. Highfill, Jillian P. Smith, Sneha Ramakrishna, Crystal L. Mackall, Alec J. Walker, Susana Galli, Rana El-Etriby, Maria Tsokos, Yongzhi Cui
Publikováno v:
Cancer Immunology Research. 4:869-880
Genetically engineered T cells expressing CD19-specific chimeric antigen receptors (CAR) have shown impressive activity against B-cell malignancies, and preliminary results suggest that T cells expressing a first-generation disialoganglioside (GD2)-s
Publikováno v:
Current Stem Cell Reports. 1:187-196
Chimeric antigen receptors (CARs) genetically link an antigen-binding domain with cell-signaling domains to redirect immune cell specificity toward antigens expressed on the surface of cancer cells. Progress in CAR engineering over the last two decad
Autor:
Jack F. Shern, Meera Murgai, Terry J. Fry, Alec J. Walker, M. Eric Kohler, Rimas J. Orentas, Crystal L. Mackall, Maria Ingaramo, Rosandra N. Kaplan, Kelsey Wanhainen, Adrienne H. Long, Waleed Haso, Jillian P. Smith, George H. Patterson, Vikas R Venkateshwara
Publikováno v:
Nature medicine
Chimeric antigen receptors (CARs) targeting CD19 have mediated dramatic antitumor responses in hematologic malignancies, but tumor regression has rarely occurred using CARs targeting other antigens. It remains unknown whether the impressive effects o